I've met many biotech founders with compelling science who struggle to gain traction with investors. Sometimes, the founders are world-leading scientists with groundbreaking discoveries, yet investors show no interest in the company. If the science is great, what gives?
Many biotech founders assume strong science will naturally attract investment. In reality, investors look beyond the science and evaluate the management team, product strategy, regulatory risk, commercial opportunity, and the potential path to a successful exit. There are many reasons investors pass on scientifically compelling opportunities. Here are a few common ones.
The science isn't communicated clearly.
Great science is not enough if investors cannot quickly understand why it matters, what problem it can uniquely solve, and why now is the right time to build the company around it. It's the founder's job to clearly communicate the key value proposition of your science to investors. And you have to do it fast before they lose interest.
The science introduces too much risk.
The world may not be ready for your revolutionary ideas. Drug discovery and development is already a risky business. An unproven technology, therapeutic modality, or development approach can make investors even more cautious.
Investors want to know whether the key risks have been identified and addressed. Can the science be reproduced? Can the product be manufactured at scale? Is there a viable regulatory path? The more uncertainty surrounding the technology, the harder it becomes for investors to underwrite the opportunity.
Breakthrough science can be exciting, but investors need to be assured that the path forward is achievable.
There is not a big enough commercial market.
You may be addressing a niche market, and the market opportunity may not be large enough to justify the risk and capital required to build the business. In other cases, the long-term opportunity may be attractive, but reimbursement, adoption, or market access challenges make the path to commercialization too uncertain.
Investors may love the science, but they also need to see a market large enough to justify the investment. Is this a niche opportunity, or the first step toward a much larger market? Will payers, providers, patients, or pharma partners ultimately support adoption?
Great science without a viable commercial opportunity rarely attracts investment.
The science is too far from becoming a drug.
Many scientific discoveries are years away from becoming a therapeutic product. An interesting target, a novel mechanism, or encouraging animal data can generate excitement, but investors know that most of the hard work still lies ahead. Lead optimization, safety assessment, manufacturability, regulatory requirements, and clinical validation all remain significant hurdles.
A startup may have excellent science, yet still be too early for many investors. The challenge is not whether the science is interesting. It is whether enough risk has been removed to justify the investment.
The team lacks urgency and execution.
Doing science takes time. Building a company takes momentum. Investors can quickly tell whether you're building a company or pursuing a science project.
Are you talking about publication more than IP protection? Are you excited about the many directions science can take you, without a clear path for one key product? Are you playing it safe, waiting for someone to write you a check before investing your time?
If you lack focus, chase every scientific possibility, and wait for the next grant before taking action, it may take years to reach a viable drug candidate.
Great science creates possibilities. Building a company requires much more.
Investors are not simply evaluating whether the science works. They are evaluating whether a team can transform that science into a product, navigate risk, create value, and ultimately deliver meaningful returns.
The same technology, in the hands of a first-time academic founder versus an experienced biotech entrepreneur, attracts very different levels of investor interest.
The strongest biotech companies combine scientific innovation with focused execution, commercial thinking, and a clear path forward.
Science may start the story, but it is rarely the whole story.